BBV152 COVID-19 vaccine

12/11/2021 - "BBV152 was highly efficacious against laboratory-confirmed symptomatic COVID-19 disease in adults. "
12/11/2021 - "The primary outcome was the efficacy of the BBV152 vaccine in preventing a first occurrence of laboratory-confirmed (RT-PCR-positive) symptomatic COVID-19 (any severity), occurring at least 14 days after the second dose in the per-protocol population. "
05/01/2023 - "This study has been done to know the clinic-biochemical profiles, radiologic findings of COVID-19 admitted patients, the predictors of mortality in the second wave, and clinical outcomes in the three waves in relation to COVAXIN vaccination status. "
05/01/2023 - "An in-depth appraisal of clinico-biochemical and radiological findings of COVID-19 patients during the COVID-19 pandemic in a dedicated COVID Care Hospital in Eastern India and its outcome in relation to the COVAXIN vaccination status: A 2-year study."
12/31/2022 - "The primary objective of the study was to estimate the effectiveness of Covaxin in preventing breakthrough SARS-CoV-2 infection in healthcare workers (HCWs). "

01/01/2022 - "Immunogenicity endpoints were compared with Biodefense and Emerging Infections, Research Resources Repository (BEI) reference serum samples and from adults who received two doses of BBV152 in the same schedule in a previously reported phase 2 study. "
01/01/2023 - "Thirty patients with hybrid immunity after BBV152 and 25 with complete vaccination without infection were included as controls. "
01/01/2021 - "In this study, we determined SARS-CoV-2-specific antibody levels at day 0 (baseline, before vaccination), day 28 ± 2 post-first dose (month 1) and day 56 ± 2 post-first dose (month 2) of BBV152 whole-virion-inactivated SARS-CoV-2 recipients, and compared the antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection to those individuals without prior evidence of infection. "
01/01/2022 - "BBV152 was well tolerated in children aged 2-18 years, and induced higher neutralising antibody responses than those observed in adults, in whom the efficacy (ie, the prevention or decrease in the severity of COVID-19 infection) has been demonstrated. "
01/01/2022 - "India started its vaccination programme for Coronavirus-19 infection (COVID-19) on 16 January 2021 with CovishieldTM (Oxford/Astra Zeneca vaccine manufactured by Serum Institute of India) and Covaxin ® (Bharat Biotech, India). "

01/01/2022 - "These findings suggest that BBV152 was associated with protection against both symptomatic and asymptomatic reinfection in HCWs after a complete vaccination schedule, when the predominant circulating variant was B.1.617.2."
01/01/2022 - "The estimated effectiveness of BBV152 against reinfection was 86% (95% CI, 77%-92%); symptomatic reinfection, 87% (95% CI, 76%-93%); and asymptomatic reinfection, 84% (95% CI, 47%-95%) among fully vaccinated HCWs. "
01/01/2022 - "To assess the incidence density of reinfection among a cohort of HCWs and estimate the effectiveness of the inactivated whole virion vaccine BBV152 against reinfection. "
01/01/2022 - "SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India."

01/01/2022 - "Hence, these results indicate that a booster dose of BBV152 is safe and necessary to ensure persistent immunity to minimize breakthrough infections of COVID-19, due to newly emerging variants.Trial"
07/01/2022 - "Prevalence, severity, and risk factor of breakthrough infection after vaccination with either the Covaxin or the Covishield among healthcare workers: A nationwide cross-sectional study."
01/01/2023 - "Here we studied circulating spike-specific T follicular response (cTfh) in infection-naïve vaccinees and convalescent vaccinees (individuals who got the Delta breakthrough infection after two doses of BBV152 vaccine) to understand their response as they are the most crucial cells that are involved in vaccine-mediated protection by helping in B-cell maturation. "
12/01/2022 - "These results demonstrate the effectiveness of Covishield and Covaxin against severe disease in patients hospitalized with COVID-19 with breakthrough infections caused by the Delta variant. "
01/01/2022 - "This year-long follow-up study found a 7- and 5-fold antibody waning in Covaxin and Covishield recipients, respectively, without any breakthrough infection history. "

08/21/2022 - "The highest and the lowest incidence of menstruation disturbances were recorded<br />in the group vaccinated with Covaxin (17.6%) and Sputnik V (5%), respectively. "
06/08/2023 - "The menstrual irregularities observed were significantly higher with the COVAXIN vaccine. "
08/21/2022 - "Present study assessed whether Sinopharm, AstraZeneca, Sputnik V, and Covaxin's vaccinated women<br />reveal a distinct incidence of menstruation disturbances, hirsutism, and metrorrhagia.<br />Materials and Methods: Data collection was performed from June to August 2021, and 427 women working in seven<br />selected hospitals in Tehran were studied in this descriptive-analytical cross-sectional study. "
08/21/2022 - "Comparison of Side Effects of COVID-19 Vaccines: Sinopharm, AstraZeneca, Sputnik V, and Covaxin in Women in Terms of Menstruation Disturbances, Hirsutism, and Metrorrhagia: A Descriptive-Analytical Cross-Sectional Study."
08/21/2022 - "There was no significant relationship between all three complications<br />incidence with the previous infection concerning all vaccines (coefficient=0.46, 1.27, -0.15 respectively for menstruation<br />disturbances, metrorrhagia, and, hirsutism).<br />Conclusion: Seemingly, Covaxin revealed the most side effects in terms of menstruation disturbances. "